Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Sana Biotechnology, Inc. before investing.

In this article, we go over a few key elements for understanding Sana Biotechnology, Inc.’s stock price such as:

• Sana Biotechnology, Inc.’s current stock price and volume
• Why Sana Biotechnology, Inc.’s stock price changed recently
• Upgrades and downgrades for SANA from analysts
• SANA’s stock price momentum as measured by its relative strength

About Sana Biotechnology, Inc. (SANA)

Before we jump into Sana Biotechnology, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Want to learn more about Sana Biotechnology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Sana Biotechnology, Inc..

What Caused Sana Biotechnology, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of October 30, 2026, there were 0 analysts who downgraded Sana Biotechnology, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Sana Biotechnology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Sana Biotechnology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Sana Biotechnology, Inc. (SANA) by visiting AAII Stock Evaluator.

Relative Price Strength of Sana Biotechnology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of October 30, 2026, Sana Biotechnology, Inc. has a weighted four-quarter relative price strength of -18.00%, which translates to a Momentum Score of 17 and is considered to be Very Weak.

Want to learn more about how Sana Biotechnology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Sana Biotechnology, Inc. Stock Price: Bottom Line

As of November 2, 2026, Sana Biotechnology, Inc.’s stock price is $2.435, which is down 5.25% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Sana Biotechnology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.